Free Trial

Akero Therapeutics (AKRO) Stock Forecast & Price Target

$26.82
-0.97 (-3.49%)
(As of 07/24/2024 ET)

Akero Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Based on 9 Wall Street analysts who have issued ratings for Akero Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 9 analysts, 1 has given a hold rating, and 8 have given a buy rating for AKRO.

Consensus Price Target

$41.13
53.34% Upside
High Forecast$56.00
Average Forecast$41.13
Low Forecast$30.00

According to the 9 analysts' twelve-month price targets for Akero Therapeutics, the average price target is $41.13. The highest price target for AKRO is $56.00, while the lowest price target for AKRO is $30.00. The average price target represents a forecasted upside of 53.34% from the current price of $26.82.

TypeCurrent Forecast
7/25/23 to 7/24/24
1 Month Ago
6/25/23 to 6/24/24
3 Months Ago
4/26/23 to 4/25/24
1 Year Ago
7/25/22 to 7/25/23
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
8 Buy rating(s)
8 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
Hold
1 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$41.13$41.13$37.71$52.40
Forecasted Upside53.34% Upside98.29% Upside62.35% Upside34.65% Upside
Get Akero Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for AKRO and its competitors with MarketBeat's FREE daily newsletter.

AKRO Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

AKRO Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Akero Therapeutics Stock vs. The Competition

TypeAkero TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.89
2.72
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside53.34% Upside2,994.90% Upside10.36% Upside
News Sentiment RatingNeutral News
Neutral News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/20/2024Cantor Fitzgerald
3 of 5 stars
 Reiterated RatingOverweight
6/11/2024Wolfe Research
3 of 5 stars
 Initiated CoverageOutperform
6/11/2024HC Wainwright
3 of 5 stars
 Reiterated RatingBuy ➝ Buy$50.00 ➝ $50.00+117.49%
5/15/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform ➝ Outperform$50.00 ➝ $38.00+87.19%
5/13/2024Canaccord Genuity Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$59.00 ➝ $56.00+169.49%
4/22/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageNeutral$30.00+44.51%
3/5/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$39.00 ➝ $42.00+41.51%
10/11/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$70.00 ➝ $33.00+111.40%
10/11/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight ➝ Overweight$62.00 ➝ $41.00+125.90%
4/11/2023Lifesci Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
P. Dolezal
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
9/13/2022Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$14.00 ➝ $25.00-9.09%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 08:34 PM ET.

AKRO Forecast - Frequently Asked Questions

What is Akero Therapeutics' forecast for 2024?

According to the research reports of 9 Wall Street equities research analysts, the average twelve-month stock price forecast for Akero Therapeutics is $41.13, with a high forecast of $56.00 and a low forecast of $30.00.

Should I buy or sell Akero Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Akero Therapeutics in the last year. There is currently 1 hold rating and 8 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "moderate buy" AKRO shares.

Does Akero Therapeutics's stock price have much upside?

According to analysts, Akero Therapeutics's stock has a predicted upside of 98.29% based on their 12-month stock forecasts.

What analysts cover Akero Therapeutics?

Akero Therapeutics has been rated by research analysts at Canaccord Genuity Group, Cantor Fitzgerald, Evercore ISI, HC Wainwright, and Wolfe Research in the past 90 days.

Do Wall Street analysts like Akero Therapeutics more than its competitors?

Analysts like Akero Therapeutics more than other "medical" companies. The consensus rating score for Akero Therapeutics is 2.89 while the average consensus rating score for "medical" companies is 2.72. Learn more on how AKRO compares to other companies.


This page (NASDAQ:AKRO) was last updated on 7/24/2024 by MarketBeat.com Staff

From Our Partners